Micro RNAs (miRNAs) play a crucial role in various cellular functions of the human body. A good example of their importance is miR-146a, an important anti-inflammatory miRNA. This was found to negatively impact osteogenesis and bone regeneration in vitro, by controlling the differentiation of mesenchymal stem cells.
The influence of miR-146a on bone stability as well as the development of osteoporosis and remodelling has not been fully delineated. Saferding et al. analysed the role of mIR-146a in bone metabolism by assessing systemic bone, tibiae, and femur of wildtype and miR-146a deficient mice (3 to 18 months of age) with histological and µCT analysis. Serum cytokine levels were analysed by ELISA, and miRNA expression levels in bone were analysed by qPCR. Ovariectomy induced bone loss was performed to induce osteoporosis. Significantly increased trabecular bone mass was seen in miR-146a deficient mice compared to wildtype animals, starting from 6 months of age, while cortical thickness of systemic bones was significantly reduced. Analysis of serum in aged miR-146a deficient animals showed elevated activity of bone-resorbing osteoclasts compared to wildtype animals. qPCR results showed elevated expression of signature molecules of osteoclasts as well as osteoblasts in aged miR-146a deficient mice, suggesting a regulatory role of miR-146a in both cell types.
Histological analysis of long bones showed significant trabecular bone loss in ovariectomised wildtype mice. However, there was no trabecular bone loss in ovariectomised miR-146a deficient animals. It was concluded by the researchers that miR-146a controls bone turnover and miR-146a deficient mice build up bone over time. Furthermore, the loss of miR-146a protects bone loss induced by oestrogen deficiency, which suggests that miR-146a may be used as a potential therapeutic target in the treatment of osteoporosis.[3]
- Saferding V, et al. Abstract SAT0072. EULAR 2018.
Posted on
Previous Article
« Low bone mineral density is common in axial spondyloarthritis; more awareness required Next Article
No significant differences when tapering TNF blockers versus csDMARDs »
« Low bone mineral density is common in axial spondyloarthritis; more awareness required Next Article
No significant differences when tapering TNF blockers versus csDMARDs »
Table of Contents: EULAR 2018
Featured articles
Rheumatoid Arthritis
Switching to biosimilar bDMARDs is safe and efficacious
No significant differences when tapering TNF blockers versus csDMARDs
Confirmation of long-term safety profile adalimumab across indications
Ankylosing Spondylitis
Clinical effect of vedolizumab on articular manifestations spondyloarthritis associated with IBD
Synergistic effect NSAIDs plus TNFi in slowing radiographic progression in ankylosing spondylitis patients
Osteoporosis and Osteoarthritis
Systemic Sclerosis and Systemic Lupus Erythematosus
Promising results rituximab in systemic sclerosis, and systemic lupus erythematosus classification criteria
Related Articles
November 22, 2024
ACR presents new guideline for lupus nephritis
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com